Laboratorios Farmaceúticos Rovi SA (LABFF)
67.17
0.00 (0.00%)
USD |
OTCM |
Oct 08, 16:00
Laboratorios Farmaceúticos Rovi Gross Profit Margin (Quarterly) : 63.56% for June 30, 2026
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 63.56% |
| March 31, 2026 | 55.56% |
| December 31, 2025 | 59.87% |
| September 30, 2025 | 66.68% |
| June 30, 2025 | 61.25% |
| March 31, 2025 | 53.66% |
| December 31, 2024 | 56.03% |
| September 30, 2024 | 66.36% |
| June 30, 2024 | 57.78% |
| March 31, 2024 | 52.29% |
| December 31, 2023 | 56.07% |
| September 30, 2023 | 60.22% |
| June 30, 2023 | 47.65% |
| March 31, 2023 | 59.62% |
| December 31, 2022 | 70.47% |
| September 30, 2022 | 56.93% |
| June 30, 2022 | 54.85% |
| March 31, 2022 | 57.94% |
| December 31, 2021 | 61.53% |
| September 30, 2021 | 61.37% |
| June 30, 2021 | 49.20% |
| March 31, 2021 | 49.48% |
| December 31, 2020 | 52.25% |
| September 30, 2020 | 52.22% |
| June 30, 2020 | 57.79% |
| Date | Value |
|---|---|
| March 31, 2020 | 49.60% |
| December 31, 2019 | 48.58% |
| September 30, 2019 | 34.50% |
| June 30, 2019 | 32.98% |
| March 31, 2019 | 29.88% |
| December 31, 2018 | 28.48% |
| September 30, 2018 | 35.98% |
| June 30, 2018 | 53.66% |
| March 31, 2018 | 53.66% |
| December 31, 2017 | 60.47% |
| September 30, 2017 | 53.75% |
| June 30, 2017 | 55.19% |
| March 31, 2017 | 56.70% |
| December 31, 2016 | 52.50% |
| September 30, 2016 | 52.65% |
| June 30, 2016 | 54.32% |
| March 31, 2016 | 55.10% |
| December 31, 2015 | 54.89% |
| September 30, 2015 | 58.32% |
| June 30, 2015 | 58.83% |
| March 31, 2015 | 54.25% |
| December 31, 2014 | 58.08% |
| September 30, 2014 | 54.74% |
| June 30, 2014 | 34.61% |
| March 31, 2014 | 30.31% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| Almirall SA | 64.43% |
| AstraZeneca PLC | 76.09% |
| ANI Pharmaceuticals, Inc. | 54.97% |
| Corcept Therapeutics, Inc. | 98.41% |
| Veru, Inc. | -- |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | 28.20% |
| Return on Assets | 19.31% |
| Return on Invested Capital | 23.86% |
| Profit Margin (Quarterly) | 39.09% |
| Operating Margin (Quarterly) | 9.42% |
| Return on Net Operating Assets | 21.87% |